Tikun Olam-Cannbit Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Tikun Olam-Cannbit Pharmaceuticals's earnings have been declining at an average annual rate of -36.4%, while the Pharmaceuticals industry saw earnings growing at 11.4% annually. Revenues have been growing at an average rate of 47.1% per year.
Key information
-36.4%
Earnings growth rate
11.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 35.1% |
| Revenue growth rate | 47.1% |
| Return on equity | -284.5% |
| Net Margin | -201.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN)
Jul 21
Would Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Be Better Off With Less Debt?
Oct 03Is Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Weighed On By Its Debt Load?
Jun 03Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Is Carrying A Fair Bit Of Debt
Oct 17Is Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Using Debt Sensibly?
May 19Shareholders Of Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Must Be Happy With Their 135% Total Return
Mar 19How Much Did Tikun Olam - Cannbit Pharmaceuticals'(TLV:TKUN) Shareholders Earn From Share Price Movements Over The Last Five Years?
Dec 02
Revenue & Expenses BreakdownBeta
How Tikun Olam-Cannbit Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 44 | -89 | 23 | 4 |
| 30 Sep 23 | 47 | -98 | 24 | 5 |
| 30 Jun 23 | 51 | -107 | 25 | 7 |
| 31 Mar 23 | 50 | -77 | 25 | 6 |
| 31 Dec 22 | 49 | -48 | 24 | 5 |
| 30 Sep 22 | 45 | -38 | 24 | 6 |
| 30 Jun 22 | 41 | -27 | 24 | 6 |
| 31 Mar 22 | 39 | -30 | 26 | 7 |
| 31 Dec 21 | 37 | -33 | 28 | 7 |
| 30 Sep 21 | 32 | -34 | 28 | 6 |
| 30 Jun 21 | 28 | -35 | 29 | 4 |
| 31 Mar 21 | 25 | -34 | 29 | 3 |
| 31 Dec 20 | 22 | -33 | 29 | 2 |
| 30 Sep 20 | 16 | -27 | 27 | 2 |
| 30 Jun 20 | 11 | -20 | 19 | 1 |
| 31 Mar 20 | 5 | -16 | 13 | 1 |
| 31 Dec 19 | 0 | -11 | 9 | 1 |
| 30 Sep 19 | 0 | -17 | 5 | 0 |
| 30 Jun 19 | 0 | -24 | 3 | 0 |
| 31 Mar 19 | 0 | -23 | 2 | 0 |
| 31 Dec 18 | 0 | -21 | 1 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
| 31 Dec 15 | 0 | -3 | 3 | 0 |
| 30 Sep 14 | 0 | -5 | 2 | 0 |
| 31 Dec 13 | 3 | -13 | 2 | 0 |
| 30 Sep 13 | 6 | -22 | 4 | 0 |
| 30 Jun 13 | 6 | -23 | 3 | 0 |
Quality Earnings: TKUN is currently unprofitable.
Growing Profit Margin: TKUN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TKUN is unprofitable, and losses have increased over the past 5 years at a rate of 36.4% per year.
Accelerating Growth: Unable to compare TKUN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TKUN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.7%).
Return on Equity
High ROE: TKUN has a negative Return on Equity (-284.53%), as it is currently unprofitable.